clene.com - CLNN Forward P/S Multiple
Clene Inc. is expanding its nanotherapeutic platforms, aiming to complete testing and attract strategic partners. The projected P/S multiple demonstrates the market valuation of these expectations, where the value 234.60 reflects the metric's balance. The business foundation consists of patents for gold nanoparticles to combat neurodegeneration, while drug synthesis is optimized using automated algorithms.
clene.com (CLNN) - metric breakdowns and financial figures
- market price and analyst price targets:
- issuer market value details:
- issuer book value statistics:
- debt level and financial liquidity data:
- net income and valuation multiples indicators:
CLNN - Company Net Income|Future Profit Clene Inc.|CLNN - P/E Multiple|Future Price to Earnings Clene|CLNN - Growth-Adjusted Payback Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Clene Inc.|CLNN - Profit before interest, taxes and amortization|Net earnings per share (EPS TTM) Clene|CLNN - Net earnings per share for the last 12 months|Year-over-year earnings per share growth for the last twelve months clene.com|CLNN - Earnings per share growth in current year|Earnings growth forecast for next year Clene Inc.
- sales volume and revenue indicators:
Fundamental company valuation:CLNN (Clene Nanomedicine)
For the biotech sector of Clene Inc. (CLNN), where valuation is driven by the potential of quantum nanocatalysts in brain therapy, the forward P/S metric serves as a key indicator of market revenue expectations. It compares current market capitalization with the consensus sales forecast, allowing investors to distinguish a fundamental reassessment of innovation value from short-term price volatility when analyzing this forward P/S metric.
Competitor analysis for Clene Inc.
Price-to-Projected Revenue Ratio Biogen BIIB|NBIX: Market Cap to Projected Revenue|Regencell - Forward P/S Multiple|Axsome Corp (AXSM) - Forward Price-to-Revenue Multiple|ACAD (ACADIA Pharmaceuticals) - Forward Price-to-Revenue Multiple|XENE - Market Cap to Expected Sales Ratio|VKTX (Viking Therapeutics, Inc.) - Forward P/S Multiple|Forward Price-to-Revenue Multiple Supernus Pharmaceuticals, Inc. (SUPN)|Price-to-Projected Revenue Ratio Catalyst Pharmaceuticals Inc (CPRX)|Price-to-Projected Revenue Ratio DNLI (Denali Corp)|Price-to-Projected Revenue Ratio Harmony Biosciences HRMY|BHVN: Market Cap to Projected Revenue|AMLX - Price-to-Projected Revenue Ratio|TRVI (Trevi Therapeutics Inc) - Market Cap to Projected Revenue|Praxis Medicines (PRAX) - Price-to-Projected Revenue Ratio|Market Cap to Projected Revenue AVXL|CBLL (CeriBell, Inc.) - Forward P/S Multiple|Market Cap to Future Revenue Ratio Prothena Corporation PRTA|Forward Price-to-Revenue Multiple ALEC (Alector, Inc.)|Forward P/S Multiple Annexon Biosciences (ANNX)|Price-to-Projected Revenue Ratio Omeros OMER|Forward Price to Sales NGNE|ACIU - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio voyagertherapeutics.com|NMRA: Forward P/S Multiple|Forward Price-to-Revenue Multiple Scilex Holding|Price-to-Projected Revenue Ratio Tevogen Bio Holdings, Inc.|Price-to-Projected Revenue Ratio ACOG|Forward P/S Multiple CGTX|IKT - Market Cap to Future Revenue Ratio|Price-to-Projected Revenue Ratio Cassava Sciences SAVA|ASRT: Market Cap to Projected Revenue|Coya - Forward P/S Multiple|Market Cap to Future Revenue Ratio Vistagen Therapeutics|OVID (ovidrx.com) - Forward Price-to-Revenue Multiple|acumenpharm.com - Forward Price to Sales|CRVO (CervoMed) - Forward P/S Multiple|Alterity Therapeutics Ltd (ATHE) - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio PepGen Inc. (PEPG)|Jupiter Neurosciences, Inc. - Market Cap to Projected Revenue|Forward P/S Multiple RLMD (Relmada Therapeutics)|ANVS - Forward Price-to-Revenue Multiple|GRCE: Forward Price-to-Revenue Multiple|Market Cap to Expected Sales Ratio Firefly Neuroscience, Inc. AIFF|KLTO: Forward P/S Multiple|Forward Price-to-Revenue Multiple NeuroSense Therapeutics Ltd.|Price-to-Projected Revenue Ratio Reviva Pharmaceuticals|Price-to-Projected Revenue Ratio MTVA|Price-to-Projected Revenue Ratio NeurAxis (NRXS)|heliusmedical.com - Market Cap to Projected Revenue|Price-to-Projected Revenue Ratio Passage Bio PASG|NEUP: Market Cap to Projected Revenue|NERV - Price-to-Projected Revenue Ratio|ATHA (athira.com) - Market Cap to Projected Revenue|ADXN: Forward P/S Multiple|Market Cap to Future Revenue Ratio Alzamend Neuro (ALZN)|Forward Price-to-Revenue Multiple CYCN|Forward P/S Multiple Protagenic|Price-to-Projected Revenue Ratio Pasithea Therapeutics (KTTA)|CRGT (cortigent.com) - Forward Price to Sales|Price-to-Projected Revenue Ratio Avenue Therapeutics, Inc. ATXI|Brainstorm Cell Therapeutics Inc. (BCLI) - Market Cap to Future Revenue Ratio|Cara Therapeutics, Inc - Forward P/S Multiple|Chromocell (CHRO) - Forward Price-to-Revenue Multiple|eliemtx.com (ELYM) - Price-to-Projected Revenue Ratio|ITCI (Intra-Cellular Therapies, Inc.) - Price-to-Projected Revenue Ratio|LBPH (Longboard Pharmaceuticals, Inc.) - Forward P/S Multiple|Market Cap to Future Revenue Ratio Marinus Pharmaceuticals Inc MRNS|Price-to-Projected Revenue Ratio NKGen (NKGN)|NeuroBo Pharma - Market Cap to Projected Revenue|Forward P/S Multiple SAGE (Sage Therapeutics, Inc.)|synaptogen.com (SNPX) - Market Cap to Future Revenue Ratio|TRVN: Forward Price-to-Revenue Multiple|Forward Price to Sales VIGL (Vigil Neuroscience)|WENA: Forward P/S Multiple|CERE - Market Cap to Expected Sales Ratio
